{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T08:40:19Z","timestamp":1771663219265,"version":"3.50.1"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018553","name":"Science and Technology Plan Project of Wenzhou, China","doi-asserted-by":"publisher","award":["Y20190144"],"award-info":[{"award-number":["Y20190144"]}],"id":[{"id":"10.13039\/501100018553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Glioblastoma multiforme (GBM) is a common malignant brain tumor with high mortality. It is urgently necessary to develop a new treatment because traditional approaches have plateaued.<\/jats:p><\/jats:sec><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Here, we identified an immune-related gene (IRG)-based prognostic signature to comprehensively define the prognosis of GBM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Glioblastoma samples were selected from the Chinese Glioma Genome Atlas (CGGA). We retrieved IRGs from the ImmPort data resource. Univariate Cox regression and LASSO Cox regression analyses were used to develop our predictive model. In addition, we constructed a predictive nomogram integrating the independent predictive factors to determine the one-, two-, and 3-year overall survival (OS) probabilities of individuals with GBM. Additionally, the molecular and immune characteristics and benefits of ICI therapy were analyzed in subgroups defined based on our prognostic model. Finally, the proteins encoded by the selected genes were identified with liquid chromatography-tandem mass spectrometry and western blotting (WB).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Six IRGs were used to construct the predictive model. The GBM patients were categorized into a high-risk group and a low-risk group. High-risk group patients had worse survival than low-risk group patients, and stronger positive associations with multiple tumor-related pathways, such as angiogenesis and hypoxia pathways, were found in the high-risk group. The high-risk group also had a low IDH1 mutation rate, high PTEN mutation rate, low 1p19q co-deletion rate and low MGMT promoter methylation rate. In addition, patients in the high-risk group showed increased immune cell infiltration, more aggressive immune activity, higher expression of immune checkpoint genes, and less benefit from immunotherapy than those in the low-risk group. Finally, the expression levels of TNC and SSTR2 were confirmed to be significantly associated with patient prognosis by protein mass spectrometry and WB.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Herein, a robust predictive model based on IRGs was developed to predict the OS of GBM patients and to aid future clinical research.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2022.902402","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T18:16:36Z","timestamp":1659032196000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Construction and validation of a glioblastoma prognostic model based on immune-related genes"],"prefix":"10.3389","volume":"13","author":[{"given":"Kate","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changjun","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianglong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhangzhang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengde","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaodong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuizhi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangfang","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/ana.22425","article-title":"Current concepts and management of glioblastoma","volume":"70","author":"Preusser","year":"2011","journal-title":"Ann Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"European organization for research and treatment of cancer brain tumor and radiotherapy groups; national cancer institute of canada clinical trials group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"929","DOI":"10.3892\/ijo.2013.1770","article-title":"Extent of resection and radiotherapy in GBM: a 1973 to 2007 surveillance, epidemiology, and end results analysis of 21,783 patients","volume":"42","author":"Zinn","year":"2013","journal-title":"Int J Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1002\/cncr.26494","article-title":"Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, epidemiology, and end results registries","volume":"118","author":"Darefsky","year":"2012","journal-title":"Cancer."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.22034\/APJCP.2017.18.1.3","article-title":"Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment","volume":"18","author":"Hanif","year":"2017","journal-title":"Asian Pac J Cancer Prev"},{"key":"B6","first-page":"iv1","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011\u20132015","volume-title":"Neuro Oncol","author":"Ostrom","year":"2018"},{"key":"B7","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1146\/annurev-immunol-032414-112043","article-title":"Innate immune recognition of cancer","volume":"33","author":"Woo","year":"2015","journal-title":"Annu Rev Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.immuni.2015.09.001","article-title":"Metabolic reprogramming of immune cells in cancer progression","volume":"43","author":"Biswas","year":"2015","journal-title":"Immunity."},{"key":"B9","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/s41571-019-0316-z","article-title":"Immunotherapeutic approaches for small-cell lung cancer","volume":"17","author":"Iams","year":"2020","journal-title":"Nat Rev Clin Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1158\/1078-0432.CCR-16-3001","article-title":"Breast cancer immunotherapy: facts and hopes","volume":"24","author":"Emens","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41571-018-0003-5","article-title":"Current state of immunotherapy for glioblastoma","volume":"15","author":"Lim","year":"2018","journal-title":"Nat Rev Clin Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"578877","DOI":"10.3389\/fimmu.2020.578877","article-title":"Immune checkpoint targeted therapy in glioma: status and hopes","volume":"11","author":"Qi","year":"2020","journal-title":"Front Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"D1049","DOI":"10.1093\/nar\/gku1179","article-title":"Gene Ontology Consortium: going forward","volume":"43","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","article-title":"KEGG: kyoto encyclopedia of genes and genomes","volume":"28","author":"Kanehisa","year":"2000","journal-title":"Nucleic Acids Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.3390\/nu12092652","article-title":"Logistic LASSO regression for dietary intakes and breast cancer","volume":"12","author":"McEligot","year":"2020","journal-title":"Nutrients."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.gpb.2020.10.005","article-title":"Chinese glioma genome atlas (CGGA): a comprehensive resource with functional genomic data from Chinese Glioma patients","volume":"19","author":"Zhao","year":"2021","journal-title":"Genom Proteom Bioinform."},{"key":"B18","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/neuonc\/nou130","article-title":"Localizing seizure-susceptible brain regions associated with low-grade gliomas using voxel-based lesion-symptom mapping","volume":"17","author":"Wang","year":"2015","journal-title":"Neuro Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"170024","DOI":"10.1038\/sdata.2017.24","article-title":"Comprehensive RNA-seq transcriptomic profiling in the malignant progression of gliomas","volume":"4","author":"Zhao","year":"2017","journal-title":"Sci Data."},{"key":"B20","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.eururo.2018.08.038","article-title":"Reporting and interpreting decision curve analysis: a guide for investigators","volume":"74","author":"Van Calster","year":"2018","journal-title":"Eur Urol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","article-title":"Maftools: efficient and comprehensive analysis of somatic variants in cancer","volume":"28","author":"Mayakonda","year":"2018","journal-title":"Genome Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods."},{"key":"B24","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1590\/1806-9282.65.3.424","article-title":"Metastasis from glioblastoma multiforme: a meta-analysis","volume":"65","author":"Cunha","year":"1992","journal-title":"Rev Assoc Med Bras."},{"key":"B25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.drup.2018.10.001","article-title":"WINDOW consortium: A path towards increased therapy efficacy against glioblastoma","volume":"40","author":"Abdul","year":"2018","journal-title":"Drug Resist Updat."},{"key":"B26","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1038\/ncomms5741","article-title":"Sequential transcriptional changes dictate safe and effective antigen-specific immunotherapy","volume":"5","author":"Burton","year":"2014","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.3390\/cancers12102983","article-title":"The confounders of cancer immunotherapy: roles of lifestyle, metabolic disorders and sociological factors","volume":"12","author":"Deshpande","year":"2020","journal-title":"Cancers."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e180798","DOI":"10.1001\/jamaoncol.2018.0798","article-title":"Speed of adoption of immune checkpoint inhibitors of programmed cell death 1 protein and comparison of patient ages in clinical practice vs pivotal clinical trials","volume":"4","author":"O'Connor","year":"2018","journal-title":"JAMA Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1093\/annonc\/mdx210","article-title":"The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1\/PD-L1 blockade","volume":"28","author":"Foy","year":"2017","journal-title":"Ann Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3683","DOI":"10.1093\/bioinformatics\/bti605","article-title":"Simpleaffy: a bioconductor package for affymetrix quality control and data analysis","volume":"21","author":"Wilson","year":"2005","journal-title":"Bioinformatics."},{"key":"B34","doi-asserted-by":"publisher","first-page":"592","DOI":"10.18632\/aging.101415","article-title":"Mining TCGA database for genes of prognostic value in glioblastoma microenvironment","volume":"10","author":"Jia","year":"2018","journal-title":"Aging."},{"key":"B35","doi-asserted-by":"publisher","first-page":"564960","DOI":"10.3389\/fonc.2021.564960","article-title":"An immune-related gene pairs signature for predicting survival in glioblastoma","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e133811","DOI":"10.1172\/jci.insight.133811","article-title":"Prognostic and predictive value of an immune infiltration signature in diffuse lower-grade gliomas","volume":"5","author":"Song","year":"2020","journal-title":"JCI Insight."},{"key":"B37","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/s41419-019-2102-3","article-title":"Tenascin-cmediated vasculogenic mimicry formation via regulation of MMP2\/MMP9 in glioma","volume":"10","author":"Cai","year":"2019","journal-title":"Cell Death Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1093\/neuonc\/","article-title":"ADAM-9 is a novel mediator of tenascin-C-stimulated invasiveness of brain tumor-initiating cells","volume":"17","author":"Sarkar","year":"2015","journal-title":"Neuro Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s40478-018-0594-1","article-title":"POLA network. Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcome","volume":"6","author":"Appay","year":"2018","journal-title":"Acta Neuropathol Commun"},{"key":"B40","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/neuonc\/nov172","article-title":"PD-L1 expression and prognostic impact in glioblastoma","volume":"18","author":"Nduom","year":"2016","journal-title":"Neuro Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e1382792","DOI":"10.1080\/2162402X.2017.1382792","article-title":"PD-1 related transcriptome profile and clinical outcome in diffuse gliomas","volume":"7","author":"Liu","year":"2017","journal-title":"Oncoimmunology."},{"key":"B42","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239.","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.902402\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T18:16:42Z","timestamp":1659032202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.902402\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,28]]},"references-count":42,"alternative-id":["10.3389\/fneur.2022.902402"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.902402","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,28]]},"article-number":"902402"}}